Developer docs
API playgroundTry for free, no card

Search company profiles

OTR Therapeutics

Full company profile

uuid006iz3r

Namestring
OTR Therapeutics
Legal namestring
OTR Therapeutics (Shanghai) Co., Ltd.
Websiteurl
otr-tx.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

OTR Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, that operates a dual-track business model combining internal drug discovery with strategic acquisition of external preclinical assets. Founded in March 2025 by Dr. Zhui Chen (ex-Abbisko Therapeutics), Dr. Shannon Chuai (ex-Burning Rock Biotech, NASDAQ: BNR), and Dr. Yuan Shi (11 years at Eli Lilly), the company is developing differentiated oral small-molecule therapeutics across oncology, immunology & inflammation, cardiometabolic diseases, and neurological diseases. Its core scientific capability is a proprietary oral small-molecule discovery platform augmented by computer-aided drug design (SBDD, ligand-based modeling, molecular dynamics, cheminformatics), RAG-based biomedical knowledge systems, and intelligent agents for literature mining and experimental design.

The company's lead asset, OTR-8100, is an oral anti-tumor small-molecule inhibitor that received IND clearance from China's NMPA in May 2026, triggering a Phase Ib/II trial in advanced malignant tumors. The pipeline is built through both internal discovery and external asset curation, including a December 2025 acquisition of a preclinical neurology program described as best-in-class potential.

OTR is pre-revenue and monetizes through partnership economics: upfront payments, preclinical/development/regulatory/commercial milestones, and tiered royalties on worldwide net sales of commercialized products. The flagship deal is a December 2025 multi-program strategic collaboration with Zealand Pharma for metabolic disease therapeutics, worth $20-30M upfront and up to $2.5B in potential milestones plus single-digit royalties, with Zealand Pharma responsible for global clinical development and commercialization while OTR retains discovery and preclinical ownership. The company is venture-backed by True Light Capital (Temasek subsidiary), LAV (Lilly Asia Ventures), Pfizer Ventures, and Sirona Capital following a $100M Series A in June 2025, and operates from a centralized R&D hub in Shanghai's Zhangjiang Hi-Tech Park with stated collaboration reach across the US, Europe, and Asia.

Short descriptiontext

OTR Therapeutics is a Shanghai-based, clinical-stage biotech founded in 2025 that develops oral small-molecule therapeutics across oncology, immunology, cardiometabolic, and neurological diseases, monetizing through pharma partnerships and royalties rather than direct commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small-molecule therapeutics, oncology drug discovery, metabolic disease therapies, clinical-stage biotechnology, drug discovery platform
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biotechnology
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership milestone payments
TypeLicensing Royalties
Description

OTR receives upfront payments and is eligible for preclinical, development, regulatory, and commercial milestone payments from partners. The Zealand Pharma partnership includes $20-30M upfront and potential milestones up to $2.5B, with majority representing commercial milestones.

otr-tx.com
2Royalty revenue from product sales
TypeLicensing Royalties
Description

OTR is eligible to receive tiered single-digit royalties on worldwide net sales of any commercialized products resulting from collaborations, such as the Zealand Pharma metabolic disease partnership.

otr-tx.com
3Future product commercialization
TypeOne Time License
Description

Pre-revenue company with potential for direct commercialization of differentiated therapies developed internally or acquired through external partnerships, targeting oncology, immunology & inflammation, and cardiometabolic diseases.

otr-tx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OTR Therapeutics discovers and acquires distinctive preclinical small-molecule assets and advances them through its proprietary oral drug discovery platform, then partners with global pharmaceutical companies for clinical development, regulatory submissions, and commercialization. Its lead asset OTR-8100, an oral anti-tumor small-molecule inhibitor, received IND clearance from China's NMPA in May 2026; pipeline programs target oncology, immunology & inflammation, cardiometabolic, and neurological diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • OTR-8100 demonstrated superior in vitro and in vivo efficacy and compelling combination therapy potential in preclinical studies
+2 more records
Product overview1 text field

OTR Therapeutics is a clinical-stage biotechnology company operating a dual-track model combining internal R&D with strategic acquisition of external innovations. The company focuses on developing differentiated therapies across three therapeutic areas: oncology, immunology & inflammation, and cardiometabolic diseases. The core product OTR-8100 is an oral anti-tumor small-molecule candidate that recently entered clinical development. The pipeline includes multiple innovative assets acquired through external partnerships, with programs spanning preclinical to early clinical stages. The company leverages its proprietary discovery platform and R&D hub in Shanghai's Zhangjiang Hi-Tech Park to accelerate development of high-impact therapies.

Product and service1 record
1OTR-8100
CategoryOncology small-molecule therapeutic
Description

A novel oral anti-tumor small-molecule inhibitor targeting multiple solid tumors; demonstrated superior in vitro and in vivo efficacy and compelling combination therapy potential in preclinical studies. Advanced into a Phase Ib/II clinical study in China in patients with advanced malignant tumors following NMPA IND clearance. Acquired by OTR through external partnership and is the company's lead clinical asset.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Multi-program strategic collaboration and license agreement to discover and develop novel therapeutics for metabolic diseases. OTR Therapeutics leverages its proprietary discovery platform to lead research and preclinical development while Zealand Pharma assumes responsibility for clinical development, regulatory submissions, and commercialization worldwide. OTR receives $20M upfront (potentially $30M), with potential total consideration up to $2.5 billion including preclinical, development, regulatory, and commercial milestones, plus tiered single-digit royalties on worldwide net sales.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Hutchmed (HUTCHMED)
TypeDirect peer
Description

Hong Kong- and Shanghai-listed biopharma developing oncology and immunology small molecules with global BD-led commercialization. Comparable China-anchored clinical-stage model with major pharma partnerships (e.g., AstraZeneca, Lilly).

TypeDirect peer
Description

Clinical-stage biotech advancing small molecules for genetic and metabolic diseases with a partnership and licensing-driven model. Comparable on stage, modality, and emphasis on capital-efficient development across multiple programs.

TypeBroad incumbent
Description

Large China-US oncology biotech with approved products (Brukinsa) and a global clinical/commercial footprint. Comparable in therapeutic focus (oncology) and Shanghai/Beijing roots, though at substantially larger scale and with direct commercialization.

TypeDirect peer
Description

Shanghai- and San Mateo-based clinical-stage biotech developing small-molecule therapies in oncology and metabolic disease. Directly comparable in geography, modality (oral small molecules), and therapeutic focus including cardiometabolic.

TypeDirect peer
Description

Platform biotech that in-licenses and develops therapeutic programs across multiple indications via subsidiary 'Vants'. Highly comparable to OTR's build-and-buy, capital-efficient, partnership-led operating model.

TypeDirect peer
Description

Shanghai-based clinical-stage biotech co-founded by OTR's CEO Dr. Zhui Chen; focused on precision oncology small molecules. Closely comparable in geography, therapeutic focus, and operating philosophy (capital-efficient R&D, BD-led model).

TypeEmerging player
Description

AI-native biotech using high-throughput biology and machine learning to advance a broad pipeline of small molecules. Comparable on the AI/ML-augmented discovery narrative and platform-based R&D model, though with much larger headcount and public listing.

TypeBroad incumbent
Description

Global incumbent with deep cardiometabolic and oncology franchises (Mounjaro/Zepbound, Verzenio). Comparable as the competitive context for OTR's metabolic and oncology ambitions and as a partner signal via LAV (Lilly Asia Ventures).

TypeDirect peer
Description

AI-driven drug discovery company also headquartered in Shanghai with a clinical-stage pipeline of small molecules. Comparable on the AI-augmented discovery platform positioning and on regional base and therapeutic breadth.

TypeBroad incumbent
Description

Global pharma with strategic venture arm (Pfizer Ventures) that participated in OTR's Series A. Comparable as both a likely future BD counterparty and as the dominant competitive benchmark across oncology, I&I, and cardiometabolic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OTR Therapeutics

Clinical-Stage Biotechnologyotr-tx.com

OTR Therapeutics is a Shanghai-based, clinical-stage biotech founded in 2025 that develops oral small-molecule therapeutics across oncology, immunology, cardiometabolic, and neurological diseases, monetizing through pharma partnerships and royalties rather than direct commercialization.

What OTR Therapeutics does

OTR Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, that operates a dual-track business model combining internal drug discovery with strategic acquisition of external preclinical assets. Founded in March 2025 by Dr. Zhui Chen (ex-Abbisko Therapeutics), Dr. Shannon Chuai (ex-Burning Rock Biotech, NASDAQ: BNR), and Dr. Yuan Shi (11 years at Eli Lilly), the company is developing differentiated oral small-molecule therapeutics across oncology, immunology & inflammation, cardiometabolic diseases, and neurological diseases. Its core scientific capability is a proprietary oral small-molecule discovery platform augmented by computer-aided drug design (SBDD, ligand-based modeling, molecular dynamics, cheminformatics), RAG-based biomedical knowledge systems, and intelligent agents for literature mining and experimental design.

The company's lead asset, OTR-8100, is an oral anti-tumor small-molecule inhibitor that received IND clearance from China's NMPA in May 2026, triggering a Phase Ib/II trial in advanced malignant tumors. The pipeline is built through both internal discovery and external asset curation, including a December 2025 acquisition of a preclinical neurology program described as best-in-class potential.

OTR is pre-revenue and monetizes through partnership economics: upfront payments, preclinical/development/regulatory/commercial milestones, and tiered royalties on worldwide net sales of commercialized products. The flagship deal is a December 2025 multi-program strategic collaboration with Zealand Pharma for metabolic disease therapeutics, worth $20-30M upfront and up to $2.5B in potential milestones plus single-digit royalties, with Zealand Pharma responsible for global clinical development and commercialization while OTR retains discovery and preclinical ownership. The company is venture-backed by True Light Capital (Temasek subsidiary), LAV (Lilly Asia Ventures), Pfizer Ventures, and Sirona Capital following a $100M Series A in June 2025, and operates from a centralized R&D hub in Shanghai's Zhangjiang Hi-Tech Park with stated collaboration reach across the US, Europe, and Asia.

OTR Therapeutics firmographics

Firmographics
Name
OTR Therapeutics
Legal name
OTR Therapeutics (Shanghai) Co., Ltd.
Website
https://otr-tx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
OTR Therapeutics is a Shanghai-based, clinical-stage biotech founded in 2025 that develops oral small-molecule therapeutics across oncology, immunology, cardiometabolic, and neurological diseases, monetizing through pharma partnerships and royalties rather than direct commercialization.
Ownership category
akta.pro rank

Where OTR Therapeutics is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices1 record

Markets served

OTR Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Partnership milestone payments: OTR receives upfront payments and is eligible for preclinical, development, regulatory, and commercial milestone payments from partners. The Zealand Pharma partnership includes $20-30M upfront and potential milestones up to $2.5B, with majority representing commercial milestones.
  2. Royalty revenue from product sales: OTR is eligible to receive tiered single-digit royalties on worldwide net sales of any commercialized products resulting from collaborations, such as the Zealand Pharma metabolic disease partnership.
  3. Future product commercialization: Pre-revenue company with potential for direct commercialization of differentiated therapies developed internally or acquired through external partnerships, targeting oncology, immunology & inflammation, and cardiometabolic diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

OTR Therapeutics product offering

Product offering

Core offering

OTR Therapeutics discovers and acquires distinctive preclinical small-molecule assets and advances them through its proprietary oral drug discovery platform, then partners with global pharmaceutical companies for clinical development, regulatory submissions, and commercialization. Its lead asset OTR-8100, an oral anti-tumor small-molecule inhibitor, received IND clearance from China's NMPA in May 2026; pipeline programs target oncology, immunology & inflammation, cardiometabolic, and neurological diseases.

Product overview

OTR Therapeutics is a clinical-stage biotechnology company operating a dual-track model combining internal R&D with strategic acquisition of external innovations. The company focuses on developing differentiated therapies across three therapeutic areas: oncology, immunology & inflammation, and cardiometabolic diseases. The core product OTR-8100 is an oral anti-tumor small-molecule candidate that recently entered clinical development. The pipeline includes multiple innovative assets acquired through external partnerships, with programs spanning preclinical to early clinical stages. The company leverages its proprietary discovery platform and R&D hub in Shanghai's Zhangjiang Hi-Tech Park to accelerate development of high-impact therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • OTR-8100 A novel oral anti-tumor small-molecule inhibitor targeting multiple solid tumors; demonstrated superior in vitro and in vivo efficacy and compelling combination therapy potential in preclinical studies. Advanced into a Phase Ib/II clinical study in China in patients with advanced malignant tumors following NMPA IND clearance. Acquired by OTR through external partnership and is the company's lead clinical asset.

Quantifiable outcome

  • OTR-8100 demonstrated superior in vitro and in vivo efficacy and compelling combination therapy potential in preclinical studies
  • +2 more outcomes

Companies that use OTR Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

OTR Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature1 record

OTR Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Zealand PharmacoreStrategic or Co-development Partner · 11 December 2025Multi-program strategic collaboration and license agreement to discover and develop novel therapeutics for metabolic diseases. OTR Therapeutics leverages its proprietary discovery platform to lead research and preclinical development while Zealand Pharma assumes responsibility for clinical development, regulatory submissions, and commercialization worldwide. OTR receives $20M upfront (potentially $30M), with potential total consideration up to $2.5 billion including preclinical, development, regulatory, and commercial milestones, plus tiered single-digit royalties on worldwide net sales.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

OTR Therapeutics competitors and assessment

Company assessment

Direct peers

  • Hutchmed (HUTCHMED): Hong Kong- and Shanghai-listed biopharma developing oncology and immunology small molecules with global BD-led commercialization. Comparable China-anchored clinical-stage model with major pharma partnerships (e.g., AstraZeneca, Lilly).
  • BridgeBio Pharma: Clinical-stage biotech advancing small molecules for genetic and metabolic diseases with a partnership and licensing-driven model. Comparable on stage, modality, and emphasis on capital-efficient development across multiple programs.
  • Terns Pharmaceuticals: Shanghai- and San Mateo-based clinical-stage biotech developing small-molecule therapies in oncology and metabolic disease. Directly comparable in geography, modality (oral small molecules), and therapeutic focus including cardiometabolic.
  • Roivant Sciences: Platform biotech that in-licenses and develops therapeutic programs across multiple indications via subsidiary 'Vants'. Highly comparable to OTR's build-and-buy, capital-efficient, partnership-led operating model.
  • Abbisko Therapeutics: Shanghai-based clinical-stage biotech co-founded by OTR's CEO Dr. Zhui Chen; focused on precision oncology small molecules. Closely comparable in geography, therapeutic focus, and operating philosophy (capital-efficient R&D, BD-led model).
  • Insilico Medicine: AI-driven drug discovery company also headquartered in Shanghai with a clinical-stage pipeline of small molecules. Comparable on the AI-augmented discovery platform positioning and on regional base and therapeutic breadth.

Broad incumbents

  • BeiGene: Large China-US oncology biotech with approved products (Brukinsa) and a global clinical/commercial footprint. Comparable in therapeutic focus (oncology) and Shanghai/Beijing roots, though at substantially larger scale and with direct commercialization.
  • Eli Lilly: Global incumbent with deep cardiometabolic and oncology franchises (Mounjaro/Zepbound, Verzenio). Comparable as the competitive context for OTR's metabolic and oncology ambitions and as a partner signal via LAV (Lilly Asia Ventures).
  • Pfizer: Global pharma with strategic venture arm (Pfizer Ventures) that participated in OTR's Series A. Comparable as both a likely future BD counterparty and as the dominant competitive benchmark across oncology, I&I, and cardiometabolic.

Emerging players

  • Recursion Pharmaceuticals: AI-native biotech using high-throughput biology and machine learning to advance a broad pipeline of small molecules. Comparable on the AI/ML-augmented discovery narrative and platform-based R&D model, though with much larger headcount and public listing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

OTR Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OTR Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

OTR Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OTR Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OTR Therapeutics

What does OTR Therapeutics do?

OTR Therapeutics discovers and acquires distinctive preclinical small-molecule assets and advances them through its proprietary oral drug discovery platform, then partners with global pharmaceutical companies for clinical development, regulatory submissions, and commercialization. Its lead asset OTR-8100, an oral anti-tumor small-molecule inhibitor, received IND clearance from China's NMPA in May 2026; pipeline programs target oncology, immunology & inflammation, cardiometabolic, and neurological diseases.

Is OTR Therapeutics a public or private company?

OTR Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was OTR Therapeutics founded?

OTR Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is OTR Therapeutics based?

OTR Therapeutics is headquartered in Shanghai, China, in the Asia region.

How does OTR Therapeutics make money?

Three revenue lines are on record. Partnership milestone payments are the primary driver. The others are royalty revenue from product sales and future product commercialization.

Who are OTR Therapeutics's main competitors?

Direct peers on record are Hutchmed (HUTCHMED), BridgeBio Pharma, Terns Pharmaceuticals, Roivant Sciences, Abbisko Therapeutics and Insilico Medicine. Broad incumbents are BeiGene, Eli Lilly and Pfizer. Recursion Pharmaceuticals is listed as an emerging player.

Does OTR Therapeutics have an API?

No public API is recorded for OTR Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Endpoints NewsNovartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugsNovartis submitted a WARN notice indicating it is reducing its headcount in New Jersey. The article also reports that OTR and LG Chem are exploring cancer drug opportunities in China, while briefly mentioning developments involving Seres, Biocytogen, Whitehawk, Boehringer Ingelheim, Prime Vector, and MindRank.BioSpaceOTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology TherapiesOTR Therapeutics and LG Chem announced a strategic collaboration to jointly identify and develop oncology assets from China. OTR will lead preclinical and early clinical development, while LG Chem will handle ex-China clinical development, regulatory strategy, and commercialization. The partnership includes upfront payments and global milestone payments for each program.ContractpharmaOTR Therapeutics, LG Chem Partner to Accelerate Novel Oncology Therapy DevelopmentOTR Therapeutics and LG Chem signed a strategic collaboration to accelerate oncology therapy development, with OTR identifying and assessing assets and leading preclinical and early clinical work in China. LG Chem will lead ex-China clinical development, regulatory strategy, and commercialization, with OTR receiving upfront payments and milestone awards.AijournOTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology TherapiesOTR Therapeutics, a clinical-stage biotechnology company, announced a strategic collaboration with LG Chem to jointly identify, evaluate, and develop novel oncology assets originating from China. Under the agreement, OTR will identify and lead preclinical and early clinical development leveraging China's R&D environment, while LG Chem will take the leading role in ex-China clinical development, regulatory strategy, and commercialization. OTR will receive upfront payments and global development and regulatory milestone payments, with the option to participate in global development and obtain a share of rights for programs entering late-stage clinical development.Laotian TimesOTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology TherapiesOTR Therapeutics, a clinical-stage biotechnology company, announced a strategic collaboration with LG Chem to jointly identify, evaluate, and develop novel oncology assets originating from China for global commercialization. Under the agreement, OTR will lead preclinical and early clinical development leveraging China's R&D capabilities, while LG Chem will manage ex-China clinical development, regulatory strategy, and commercialization, with OTR receiving upfront and milestone payments plus an option to co-develop late-stage programs. The partnership aims to accelerate the translation of early-stage Chinese biopharma innovations into globally competitive oncology therapies for patients with unmet medical needs.PR Newswire APACOTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology TherapiesOTR Therapeutics, a clinical-stage biotechnology company, has entered into a strategic collaboration with LG Chem to identify, evaluate, and develop novel oncology assets from China. Under the agreement, OTR will lead preclinical and early clinical development leveraging China's R&D environment, while LG Chem will handle ex-China clinical development, regulatory strategy, and commercialization, with OTR receiving upfront and milestone payments. The partnership aims to accelerate the translation of innovative science into globally competitive oncology medicines for patients with significant unmet medical needs.PR NewswireOTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology TherapiesOTR Therapeutics, a clinical-stage biotechnology company, has entered into a strategic collaboration with LG Chem to jointly identify, evaluate, and develop novel oncology assets originating from China. Under the agreement, OTR will lead preclinical and early clinical development leveraging China's R&D environment, while LG Chem will take the lead in ex-China clinical development, regulatory strategy, and commercialization. OTR will receive upfront payments and be entitled to global development and regulatory milestone payments, with the option to participate in late-stage global development and obtain a share of global rights.MorningstarOTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology TherapiesOTR Therapeutics and LG Chem announced a strategic collaboration to jointly identify and develop novel oncology assets from China. OTR will lead preclinical and early clinical development, while LG Chem will handle ex-China clinical development, regulatory strategy, and commercialization. The partnership includes upfront payments and global development milestone payments.TaylorwessingBiopharma partnering update: Q4 2025The Q4 2025 biopharma partnering update highlights several significant licensing and collaboration deals, with Takeda Pharmaceutical and Innovent Biologics announcing the quarter's landmark agreement worth up to US$11.4 billion for three solid tumor drug candidates including the antibody-drug conjugate IBI343 and immuno-oncology drug IBI363. Other notable deals include Zenas BioPharma's global licensing agreement with InnoCare Pharma for BTK inhibitor Orelabrutinib (valued over US$2 billion), Novartis partnering with Relation Therapeutics on AI-enabled discovery for atopic diseases (up to US$1.7 billion), Biogen acquiring rights to Vanqua Bio's C5aR1 antagonist (nearly US$1 billion), and Zealand Pharma collaborating with OTR Therapeutics for oral metabolic disease therapeutics (up to US$2.5 billion).Longevity.TechnologyZealand links with China biotech in $20m metabolic discovery dealDanish biotech Zealand Pharma has entered a discovery and development agreement with Shanghai-based OTR Therapeutics, committing at least $20 million upfront to identify new drug targets for metabolic diseases. The collaboration allows OTR to advance programs through preclinical development, after which Zealand will take over clinical-stage assets as part of its 'Metabolic Frontier 2030' strategy. This deal aligns with Zealand's broader efforts to expand its pipeline in the competitive obesity and metabolic disease sector while awaiting key clinical data for existing partners.